All In Biotech

Drug Trial Radar · NCT00712348

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase

Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31

Actual

Start

Dec 2008

Primary completion

Apr 2013

Study completion May 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.

Conditions

  • Gaucher Disease

Interventions

  • Taliglucerase alfaDrug

    Intravenous infusion every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HemoglobinTime frame: Every 3 months from Baseline to Month 9

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • University Research Foundation for Lysosomal Storage Diseases, Inc.

    Coral Springs, Florida

  • Department of Human Genetics, Emory University School of Medicine

    Decatur, Georgia

  • Neurogenetics, NYU at Rivergate

    New York, New York

  • Bone Marrow Transplant Service, The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Rambam Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Sala de Hematologia, Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust

    Cambridge, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.